An effective VEGF-siRNA delivery via folic acid decorated and pegylated silica nanoparticles

Ultav G., TONBUL H., ŞALVA E.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.76, 2022 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 76
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.jddst.2022.103828
  • Dergi Adı: JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, EMBASE
  • Anahtar Kelimeler: Silica nanoparticles, siRNA, Gene delivery, Folic acid, Anti-VEGF, ENDOTHELIAL GROWTH-FACTOR, BREAST-CANCER, TOXICITY, DESIGN
  • İnönü Üniversitesi Adresli: Evet

Özet

Limitation of tumor vascularization can be helpful for cancer treatment. Silica nanoparticles can be produced in small diameters with good reproducibility, stability, and biocompatibility. Also, silica nanoparticles (SNPs) can be easily modified to carry negatively-charged oligonucleotides such as DNA or RNA and can be targeted to the tumor site by active targeting. In this study, we aimed to develop a gene delivery system exploiting the high amounts of folic acid receptors on breast cancer cells. Small-sized SNPs were synthesized and surface modifi-cations were performed by amination, PEGylation and folic acid conjugation (about 30 nm in diameter). Folic -acid conjugated SNPs (SNP-FA) complexed with VEGF-siRNA. Folic acid conjugation increased the cellular up-take by cancer cells (MDA-MB-231 and HeLa) according to the flow cytometer and fluorescence microscopy results. The VEGF gene silencing efficiency was determined by an ELISA and SNP-FA showed 73% and 50% gene silencing efficiency at HeLa and MDA-MB-231 cell lines, respectively. The results showed that SNPs with a suitable surface modification can be a good candidate for gene delivery.